

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

**(1) CHANGE OF ADDRESS OF PRINCIPAL PLACE  
OF BUSINESS IN HONG KONG; AND  
(2) DISCLOSEABLE TRANSACTION — COMPLETION OF THE  
ASSET TRANSACTION RELATED TO VACCINES  
IRELAND FACILITY**

**CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board of directors (the “**Board**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”) hereby announces that with effect from April 1, 2025, the address of the Company’s principal place of business in Hong Kong will change to 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

**DISCLOSEABLE TRANSACTION — COMPLETION OF THE ASSET  
TRANSACTION RELATED TO VACCINES IRELAND FACILITY**

Reference is made to the announcement (the “**Announcement**”) of the Company dated January 6, 2025 regarding the discloseable transaction in connection with the Asset Transaction related to Vaccines Ireland Facility. Unless the context requires otherwise, capitalized terms used in this announcement have the same meanings as those defined in the Announcement.

***Completion of the Asset Transaction***

The Company is pleased to announce that the Completion of the Asset Transaction has taken place on March 31, 2025 in accordance with the terms of the Agreement.

### ***Further information on the Consideration***

The Company would like to supplement with the following information in relation to the Consideration. Pursuant to the Agreement, the total Consideration is in the sum of US\$499.63 million, which consists of: (a) the payment of a sum of US\$407.00 million by the Purchaser to the Vendor at Completion; (b) the payment of an escrow amount of US\$30.00 million by the Purchaser at Completion pending release to the Vendor upon the expiry of eighteen months after Completion, subject to any downward adjustments to the Consideration due to any claims by the Purchaser if there are any breach of warranties or other obligations of the Vendor under the Agreement; and (c) the offset of the remaining balance against a sum of US\$62.63 million, being the advance previously received by the Vendor from the Purchaser after amortization as shown in the latest available financial statements of the Vendor as at the date of the Announcement.

Save as disclosed above, all information contained in the Announcement remains unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, April 1, 2025

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen as executive Director; Dr. Ge Li, Dr. Weichang Zhou, Mr. Yanling Cao and Ms. Jingwen Miao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

\* *For identification purpose only*